)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Alto Neuroscience
Alto Neuroscience (ANRO) investor relations material
Alto Neuroscience Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary10 Apr, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on personalized psychiatry using a proprietary Precision Psychiatry Platform to identify brain-based biomarkers for targeted treatments.
Pipeline includes seven clinical-stage assets targeting major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson's disease.
Product candidates are advanced based on preclinical and clinical data suggesting potential improvements over current standard-of-care medications.
Financial performance and metrics
Raised approximately $120 million in gross proceeds from a private placement in March 2026, selling 2,900,000 shares and pre-funded warrants for 3,100,000 shares at $20.00 per share.
As of March 17, 2026, had 34,845,516 shares of common stock outstanding.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of shares by selling stockholders, except for nominal proceeds from any cash exercise of pre-funded warrants.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Alto Neuroscience
- Biomarker-guided neuropsychiatric pipeline targets major unmet needs with late-stage trials ahead.ANRO
Corporate presentation2 Apr 2026 - Shareholders will vote on director elections, auditor ratification, and key equity plan amendments.ANROProxy filing26 Mar 2026
- Virtual meeting to vote on directors, auditor, and equity plan amendments, all board-backed.ANROProxy filing26 Mar 2026
- ALTO-207 advances in TRD with rapid titration, strong efficacy, and key pipeline catalysts ahead.ANROStifel 2026 Virtual CNS Forum17 Mar 2026
- Biomarker-driven CNS drug portfolio advances multiple late-stage trials with strong financial runway.ANROCorporate presentation16 Mar 2026
- ALTO-207 acquisition and robust cash support multiple pivotal trials through 2028.ANROQ4 202516 Mar 2026
- Lead programs in depression and schizophrenia advance with biomarker-driven trials and pivotal data ahead.ANROTD Cowen 46th Annual Health Care Conference3 Mar 2026
- Phase IIb data for a precision biomarker-driven depression therapy expected in late 2024.ANROJefferies 2024 Global Healthcare Conference1 Feb 2026
- ALTO-100 targets MDD with poor cognition; Phase 2b data expected Oct. 2024, strong market interest.ANROInvestor Day 202421 Jan 2026
Next Alto Neuroscience earnings date
Q1 202614 May, 2026
Alto Neuroscience
Next Alto Neuroscience earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage